MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

Search

Compugen Ltd

Cerrado

1.55 -8.28

Resumen

Variación precio

24h

Actual

Mínimo

1.53

Máximo

1.6

Métricas clave

By Trading Economics

Ingresos

-1.1M

-7.2M

Ventas

813K

2.3M

P/B

Media del Sector

60.333

39.564

Margen de beneficio

-314.405

Empleados

74

EBITDA

-912K

-8.4M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+340.25% upside

Dividendos

By Dow Jones

Próximas Ganancias

5 ago 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

-526M

161M

Apertura anterior

9.83

Cierre anterior

1.55

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

Compugen Ltd Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

11 jul 2025, 22:19 UTC

Adquisiciones, fusiones, absorciones

FCC Approves U.S. Cellular Sale to T-Mobile

11 jul 2025, 17:28 UTC

Principales Movimientos del Mercado

SharpLink Gaming Gains on Ethereum Purchase

11 jul 2025, 16:57 UTC

Ganancias

BASF Cuts Outlook on Global Economy Uncertainty

13 jul 2025, 23:54 UTC

Charlas de Mercado

Oil Edges Higher Amid Supply Disruption Worries -- Market Talk

13 jul 2025, 23:49 UTC

Charlas de Mercado

Nikkei May Fall Amid U.S. Tariff Uncertainty -- Market Talk

13 jul 2025, 23:49 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

13 jul 2025, 23:40 UTC

Charlas de Mercado

Market Talk Roundup: Latest on U.S. Politics

13 jul 2025, 23:40 UTC

Charlas de Mercado

Gold Advances Amid Rising Trade Tensions -- Market Talk

13 jul 2025, 23:39 UTC

Charlas de Mercado

China's Growth Momentum Likely Slowed in 2Q -- Market Talk

13 jul 2025, 23:16 UTC

Ganancias

China Shenhua Energy 1H 2024 Net Was CNY32.8B>1088.HK

13 jul 2025, 23:16 UTC

Ganancias

China Shenhua Energy: Drop in Coal Prices Weighed on Results >1088.HK

13 jul 2025, 23:16 UTC

Ganancias

China Shenhua Energy Sees 1H Net CNY25.6B-Net CNY27.6B >1088.HK

13 jul 2025, 23:13 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

13 jul 2025, 23:13 UTC

Charlas de Mercado

Ryman Healthcare Could Be Turning a Corner -- Market Talk

13 jul 2025, 11:00 UTC

Adquisiciones, fusiones, absorciones

The Private-Equity Maneuver Allowing More Investors to Cash Out -- WSJ

12 jul 2025, 02:24 UTC

Adquisiciones, fusiones, absorciones

Google to Pay $2.4 Billion in Deal to License Tech of Coding Startup, Hire CEO -- Update

12 jul 2025, 02:05 UTC

Adquisiciones, fusiones, absorciones

Google to Pay $2.4 Billion in Deal to License Tech of Coding Startup, Hire CEO -- WSJ

12 jul 2025, 02:05 UTC

Adquisiciones, fusiones, absorciones

Google to Hire Windsurf CEO and Other Employees, Company Says -- WSJ

12 jul 2025, 02:05 UTC

Adquisiciones, fusiones, absorciones

Google to Pay About $2.4 Billion in Deal to License Tech of AI Coding Startup, Sources Say -- WSJ

11 jul 2025, 21:45 UTC

Charlas de Mercado

Fitch Affirms Germany's Rating, Sees Deficit, Debt Rising -- Market Talk

11 jul 2025, 19:46 UTC

Adquisiciones, fusiones, absorciones

Kraft Heinz Might Split Up, Report Says. What Investors Need to Know. -- Barrons.com

11 jul 2025, 19:45 UTC

Charlas de Mercado

Crude Futures Post Back-to-Back Weekly Gains -- Market Talk

11 jul 2025, 19:05 UTC

Charlas de Mercado

U.S. Natural Gas Futures Post Third Straight Weekly Loss -- Market Talk

11 jul 2025, 18:18 UTC

Charlas de Mercado

Canada Officials Tight-Lipped on Next Steps in Trump Trade Talks -- Market Talk

11 jul 2025, 17:35 UTC

Charlas de Mercado

Canada Should Target Lower Sectoral Tariffs, Import Quotas in US Trade Talks -- Market Talk

11 jul 2025, 17:26 UTC

Charlas de Mercado

U.S. Oil Rig Count Down by 1 to 424 -- Market Talk

11 jul 2025, 16:53 UTC

Charlas de Mercado

Crude Futures Add to Early Gains -- Market Talk

11 jul 2025, 16:42 UTC

Ganancias

BASF Cuts Outlook on Global Economic Uncertainty

11 jul 2025, 16:08 UTC

Charlas de Mercado

Rise in Canadian Staycations May Help Explain Labor Market Strength -- Market Talk

11 jul 2025, 16:05 UTC

Ganancias

BASF Will Publish Half-Year Results on July 30

Comparación entre iguales

Cambio de precio

Compugen Ltd Esperado

Precio Objetivo

By TipRanks

340.25% repunte

Estimación a 12 meses

Media 7 USD  340.25%

Máximo 10 USD

Mínimo 4 USD

De acuerdo con 3 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Compugen Ltd Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

3 ratings

3

Comprar

0

Mantener

0

Vender

Puntuación técnica

By Trading Central

1.25 / 1.48Soporte y Resistencia

Corto Plazo

Very Strong Bearish Evidence

Medio plazo

Very Strong Bearish Evidence

Largo Plazo

Weak Bearish Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Compugen Ltd

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.